PubMed Health⌕ Search

Biomedical subjects

M A Jonas

Publications and source records attributed to M A Jonas.

6 recordsLinked to original sources
PubMed1994

The benefits of aspirin in acute myocardial infarction. Still a well-kept secret in the United States.

Acute myocardial infarction (MI) remains far and away the leading cause of death in the United States, and is responsible for approximately 500,000 annual fatalities. However, mortality due to MI has declined substantially in recent decades, owing to advances in treatment as well as prevention. Low-dose aspirin as well as thrombolytic therapy given during acute evolving MI each decrease mortality by about one quarter. Both therapies remain underutilized in the United States. Aspirin can be given to virtually all patients, has a far more favorable safety profile than thrombolysis, and confers a comparable benefit at a small fraction of the cost of thrombolytic agents. The more widespread use of aspirin in acute MI is one of the most important and timely clinical challenges in the United States.

Aspirin↗
PubMed1993

Antiplatelet therapy and risk of stroke.

Antiplatelet therapy, especially with aspirin, reduces the risks of occlusive vascular disease, including ischemic stroke. In an overview of 25 trials of antiplatelet therapy in patients with prior cardiovascular disease, antiplatelet treatment reduced subsequent nonfatal stroke by 27% (P = 0.0001), nonfatal myocardial infarction by 32% (P = 0.0001), and all vascular deaths by 15% (P = 0.0003), with no evidence that other antiplatelet agents were more effective than aspirin, or that higher aspirin doses (900 to 1500 mg daily) were more effective than 300 mg, the lowest daily dose tested. If begun during the acute phase of myocardial infarction, aspirin reduces nonfatal stroke by 46% (P < 0.01) and vascular deaths by 23% (P < 0.00001) after 5 weeks. In primary prevention, currently available data are inconclusive regarding the effect of aspirin therapy on stroke. However, any potential benefit on ischemic stroke must be weighed against the possibility that aspirin could increase the risk of the less common, but clinically more severe, strokes of hemorrhagic etiology.

Aspirin↗
PubMed1993

Antioxidants and cardiovascular disease: a review.

In spite of the significant decline in cardiovascular disease (CVD) mortality over the past several decades, CVD remains the leading cause of death in the United States. Although age-specific CVD rates are higher in men than women, CVD is nonetheless the leading cause of death for both sexes, and is responsible for approximately one-third of all fatalities in women as well as men. Antioxidant vitamins are a promising area of current research in the prevention of CVD. The postulated mechanism for such an effect derives from basic research demonstrating the ability of antioxidants to inhibit the oxidation of low-density lipoprotein cholesterol. Epidemiologic studies that have explored the antioxidant vitamin hypothesis include descriptive and cross-sectional studies, analytic investigations using case-control and prospective cohort study designs, as well as several small randomized clinical trials. Findings from these studies are not totally consistent, but generally support the hypothesis that antioxidant vitamins reduce the risk of CVD. Overall, there are fewer data in women than men. Large-scale randomized trials are now ongoing that will provide reliable evidence on this question. The ongoing Physicians' Health Study of over 22,000 men is testing beta-carotene, while the recently begun Women's Health Study of 40,000 women will test, utilizing a factorial design, beta-carotene as well as vitamin E. A trial has also recently been funded to test beta-carotene, vitamin E and vitamin C in secondary prevention among a high-risk population of 8,000 women with prior CVD events.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗